Price Alert

Repligen Corporation (RGEN)

NASDAQ: RGEN · Real-Time Price · USD

119.65

-1.91 (-1.57%)

At close: Aug 21, 2025, 3:59 PM

119.65

0.00%

After-hours: Aug 21, 2025, 04:30 PM EDT

-1.57% (1D)

Bid	118
Market Cap	6.73B
Revenue (ttm)	673.96M
Net Income (ttm)	-13.83M
EPS (ttm)	-0.26
PE Ratio (ttm)	-460.19
Forward PE	55.5
Analyst	Buy

Ask	130
Volume	396,588
Avg. Volume (20D)	821,183
Open	121.23
Previous Close	121.56
Day's Range	119.29 - 121.44
52-Week Range	102.97 - 182.52
Beta	1.05

About RGEN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RGEN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RGEN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Repligen Corporation is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

+4.72%

Repligen shares are trading higher after the compa... Unlock content with Pro Subscription

5 months ago

-5.54%

Repligen shares are trading lower. Evercore ISI Group initiated coverage on the stock with an In-Line rating.

News

1 week ago · seekingalpha.com

Repligen Corporation: Still Navigating Through The Covid Cliff

Repligen Corporation's Q2 results beat revenue expectations driven by strong revenue growth from consumables and biopharma sales. The company has diversified its product portfolio and customer base th...

3 weeks ago · benzinga.com

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

Repligen RGEN has been in a steady downtrend for over 1400 days. Adhishthana principles suggest the weakness is likely to continue.

3 weeks ago · seekingalpha.com

Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript

Repligen Corporation (NASDAQ:RGEN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jacob Johnson - Corporate Participant Jason K. Garland - CFO & Chief Compliance Offic...

3 weeks ago · zacks.com

Repligen (RGEN) Lags Q2 Earnings Estimates

Repligen (RGEN) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.33 per share a year ago.

1 month ago · zacks.com

Here's Why Repligen (RGEN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2 months ago · businesswire.com

908 Devices Appoints Christopher D. Brown to its Board of Directors

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, ...

2 months ago · zacks.com

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?